What's in Kyowa Kirin Co., Ltd.'s pipeline?

Kyowa Kirin Co., Ltd. has 43 drugs in our index: 3 marketed, 0 filed, 11 in Phase 3, 10 in Phase 2, 19 in Phase 1.

Which companies overlap with Kyowa Kirin Co., Ltd.'s portfolio?

Top competitors by shared drug class: GlaxoSmithKline, National and Kapodistrian University of Athens, Ain Shams University, Bayer, London School of Hygiene and Tropical Medicine.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/kyowa-kirin-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Kyowa Kirin Co., Ltd. — Portfolio Competitive Intelligence Brief

Kyowa Kirin Co., Ltd. pipeline: 3 marketed, 0 filed, 11 Phase 3, 10 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 11 Phase 3 10 Phase 2 19 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Mitozytrex	MITOMYCIN	marketed	Alkylating Drug [EPC]	Indoleamine 2,3-dioxygenase 1	Oncology	1981-01-01
KHK4827-Active	KHK4827-Active	marketed
KRN23	KRN23	marketed	FGF23 inhibitor (monoclonal antibody)	FGF23 (Fibroblast Growth Factor 23)	Endocrinology / Rare Metabolic Disorders
KW-6500	KW-6500	phase 3	Growth hormone secretagogue	Ghrelin receptor (GHS-R1a)	Endocrinology
KK8398	KK8398	phase 3	Complement C5a receptor antagonist	C5aR1 (C5a receptor 1)	Immunology
saxaglipitin	saxaglipitin	phase 3			Other
KHK7791	KHK7791	phase 3	Factor XIa inhibitor	Factor XIa	Cardiovascular
KW-2246 (fentanyl citrate)	KW-2246 (fentanyl citrate)	phase 3	Opioid analgesic	Mu (μ) opioid receptor	Pain Management
KHK7580	KHK7580	phase 3	Factor XIa inhibitor	Factor XIa	Cardiovascular
KHK4827	KHK4827	phase 3	Factor XIa inhibitor	Factor XIa	Cardiovascular
Plasma-derived antithrombin	Plasma-derived antithrombin	phase 3	Anticoagulant	Thrombin, Factor Xa	Cardiovascular
EN3267	EN3267	phase 3	C5a receptor antagonist	C5aR1 (C5a receptor 1)	Immunology

Therapeutic area mix

Cardiovascular · 4
Immunology · 3
Oncology · 2
Endocrinology · 1
Endocrinology / Rare Metabolic Disorders · 1
Diabetes · 1
Other · 1
Pain Management · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

2026-07-19 — Mitozytrex · 8186511 · Formulation · US
2026-07-19 — Mitozytrex · 9205075 · Formulation · US
2028-01-02 — Mitozytrex · 9539241 · Compound · US
2029-02-01 — Mitozytrex · 7806265 · Formulation · US
2029-05-21 — Mitozytrex · 9649428 · Method of Use · US
2031-01-20 — Mitozytrex · 12268745 · Method of Use · US
2031-01-20 — Mitozytrex · 12440568 · Method of Use · US
2031-01-20 — Mitozytrex · 9040074 · Formulation · US
2031-01-20 — Mitozytrex · 9950069 · Formulation · US
2031-01-20 — Mitozytrex · 10039832 · Method of Use · US

Competitive overlap (companies sharing drug classes)

GlaxoSmithKline · 3 shared drug classes
National and Kapodistrian University of Athens · 2 shared drug classes
Ain Shams University · 2 shared drug classes
Bayer · 2 shared drug classes
London School of Hygiene and Tropical Medicine · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Astellas Pharma Inc · 2 shared drug classes
Pfizer · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Kyowa Kirin Co., Ltd.:

Cite this brief

Drug Landscape (2026). Kyowa Kirin Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kyowa-kirin-co-ltd. Accessed 2026-05-16.